Hyderabad: Candidates for Intra-Nasal Vaksin Covid-19 First India BBV154, which is being developed by Bharat Biotech along with the University of Washington in St.
Louis, has received approval from the drug regulator to conduct human clinical testing phase II / III.
Bharat Biotech recently completed the phase I clinical trial of the ChancanZee Adenovirus vaccine in healthy volunteers in the 18-60 year age group.
According to the Ministry of Science and technology, the dosage given to volunteers in the phase test i “well tolerated”.
“There are no serious side effects (is) reported.
Previously, the vaccine was found safe, immunogenic and well tolerated in pre-clinical toxicity studies.
This vaccine is able to obtain high-level neutralization antibodies in research on animals,” he said.
The ministry said the regulatory approval was granted to conduct phase-2 clinical trials randomly, multi-centric, clinical combination of heterologous Boost from the SARS-COV-2 vaccine to evaluate the immunogenicity and BBV152 (covaxin) security with BBV154 in healthy volunteers.
The development of intra-nose vaccines has been supported by the Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIAC), he said.